328 related articles for article (PubMed ID: 22732922)
1. Effect of histone deacetylase inhibitors on HIV production in latently infected, resting CD4(+) T cells from infected individuals receiving effective antiretroviral therapy.
Blazkova J; Chun TW; Belay BW; Murray D; Justement JS; Funk EK; Nelson A; Hallahan CW; Moir S; Wender PA; Fauci AS
J Infect Dis; 2012 Sep; 206(5):765-9. PubMed ID: 22732922
[TBL] [Abstract][Full Text] [Related]
2. In vivo analysis of the effect of panobinostat on cell-associated HIV RNA and DNA levels and latent HIV infection.
Tsai P; Wu G; Baker CE; Thayer WO; Spagnuolo RA; Sanchez R; Barrett S; Howell B; Margolis D; Hazuda DJ; Archin NM; Garcia JV
Retrovirology; 2016 May; 13(1):36. PubMed ID: 27206407
[TBL] [Abstract][Full Text] [Related]
3. In Vitro Reactivation of Replication-Competent and Infectious HIV-1 by Histone Deacetylase Inhibitors.
Banga R; Procopio FA; Cavassini M; Perreau M
J Virol; 2016 Feb; 90(4):1858-71. PubMed ID: 26656693
[TBL] [Abstract][Full Text] [Related]
4. Innate Immune Activity Correlates with CD4 T Cell-Associated HIV-1 DNA Decline during Latency-Reversing Treatment with Panobinostat.
Olesen R; Vigano S; Rasmussen TA; Søgaard OS; Ouyang Z; Buzon M; Bashirova A; Carrington M; Palmer S; Brinkmann CR; Yu XG; Østergaard L; Tolstrup M; Lichterfeld M
J Virol; 2015 Oct; 89(20):10176-89. PubMed ID: 26223643
[TBL] [Abstract][Full Text] [Related]
5. The histone deacetylase inhibitor vorinostat (SAHA) increases the susceptibility of uninfected CD4+ T cells to HIV by increasing the kinetics and efficiency of postentry viral events.
Lucera MB; Tilton CA; Mao H; Dobrowolski C; Tabler CO; Haqqani AA; Karn J; Tilton JC
J Virol; 2014 Sep; 88(18):10803-12. PubMed ID: 25008921
[TBL] [Abstract][Full Text] [Related]
6. Short Communication: The Broad-Spectrum Histone Deacetylase Inhibitors Vorinostat and Panobinostat Activate Latent HIV in CD4(+) T Cells In Part Through Phosphorylation of the T-Loop of the CDK9 Subunit of P-TEFb.
Jamaluddin MS; Hu PW; Jan Y; Siwak EB; Rice AP
AIDS Res Hum Retroviruses; 2016 Feb; 32(2):169-73. PubMed ID: 26727990
[TBL] [Abstract][Full Text] [Related]
7. Gene expression and viral prodution in latently infected, resting CD4+ T cells in viremic versus aviremic HIV-infected individuals.
Chun TW; Justement JS; Lempicki RA; Yang J; Dennis G; Hallahan CW; Sanford C; Pandya P; Liu S; McLaughlin M; Ehler LA; Moir S; Fauci AS
Proc Natl Acad Sci U S A; 2003 Feb; 100(4):1908-13. PubMed ID: 12552096
[TBL] [Abstract][Full Text] [Related]
8. Histone deacetylase inhibitor romidepsin induces HIV expression in CD4 T cells from patients on suppressive antiretroviral therapy at concentrations achieved by clinical dosing.
Wei DG; Chiang V; Fyne E; Balakrishnan M; Barnes T; Graupe M; Hesselgesser J; Irrinki A; Murry JP; Stepan G; Stray KM; Tsai A; Yu H; Spindler J; Kearney M; Spina CA; McMahon D; Lalezari J; Sloan D; Mellors J; Geleziunas R; Cihlar T
PLoS Pathog; 2014 Apr; 10(4):e1004071. PubMed ID: 24722454
[TBL] [Abstract][Full Text] [Related]
9. Ex Vivo Bioactivity and HIV-1 Latency Reversal by Ingenol Dibenzoate and Panobinostat in Resting CD4(+) T Cells from Aviremic Patients.
Spivak AM; Bosque A; Balch AH; Smyth D; Martins L; Planelles V
Antimicrob Agents Chemother; 2015 Oct; 59(10):5984-91. PubMed ID: 26169416
[TBL] [Abstract][Full Text] [Related]
10. Decay of the HIV reservoir in patients receiving antiretroviral therapy for extended periods: implications for eradication of virus.
Chun TW; Justement JS; Moir S; Hallahan CW; Maenza J; Mullins JI; Collier AC; Corey L; Fauci AS
J Infect Dis; 2007 Jun; 195(12):1762-4. PubMed ID: 17492591
[TBL] [Abstract][Full Text] [Related]
11. Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.
Archin NM; Liberty AL; Kashuba AD; Choudhary SK; Kuruc JD; Crooks AM; Parker DC; Anderson EM; Kearney MF; Strain MC; Richman DD; Hudgens MG; Bosch RJ; Coffin JM; Eron JJ; Hazuda DJ; Margolis DM
Nature; 2012 Jul; 487(7408):482-5. PubMed ID: 22837004
[TBL] [Abstract][Full Text] [Related]
12. Maraviroc Is Associated with Latent HIV-1 Reactivation through NF-κB Activation in Resting CD4
Madrid-Elena N; García-Bermejo ML; Serrano-Villar S; Díaz-de Santiago A; Sastre B; Gutiérrez C; Dronda F; Coronel Díaz M; Domínguez E; López-Huertas MR; Hernández-Novoa B; Moreno S
J Virol; 2018 May; 92(9):. PubMed ID: 29444937
[TBL] [Abstract][Full Text] [Related]
13. Reservoirs for HIV-1: mechanisms for viral persistence in the presence of antiviral immune responses and antiretroviral therapy.
Pierson T; McArthur J; Siliciano RF
Annu Rev Immunol; 2000; 18():665-708. PubMed ID: 10837072
[TBL] [Abstract][Full Text] [Related]
14. Activation of HIV transcription with short-course vorinostat in HIV-infected patients on suppressive antiretroviral therapy.
Elliott JH; Wightman F; Solomon A; Ghneim K; Ahlers J; Cameron MJ; Smith MZ; Spelman T; McMahon J; Velayudham P; Brown G; Roney J; Watson J; Prince MH; Hoy JF; Chomont N; Fromentin R; Procopio FA; Zeidan J; Palmer S; Odevall L; Johnstone RW; Martin BP; Sinclair E; Deeks SG; Hazuda DJ; Cameron PU; Sékaly RP; Lewin SR
PLoS Pathog; 2014 Oct; 10(10):e1004473. PubMed ID: 25393648
[TBL] [Abstract][Full Text] [Related]
15. Persistence of wild-type virus and lack of temporal structure in the latent reservoir for human immunodeficiency virus type 1 in pediatric patients with extensive antiretroviral exposure.
Ruff CT; Ray SC; Kwon P; Zinn R; Pendleton A; Hutton N; Ashworth R; Gange S; Quinn TC; Siliciano RF; Persaud D
J Virol; 2002 Sep; 76(18):9481-92. PubMed ID: 12186930
[TBL] [Abstract][Full Text] [Related]
16. The Pathway To Establishing HIV Latency Is Critical to How Latency Is Maintained and Reversed.
Rezaei SD; Lu HK; Chang JJ; Rhodes A; Lewin SR; Cameron PU
J Virol; 2018 Jul; 92(13):. PubMed ID: 29643247
[TBL] [Abstract][Full Text] [Related]
17. Stimulating the RIG-I pathway to kill cells in the latent HIV reservoir following viral reactivation.
Li P; Kaiser P; Lampiris HW; Kim P; Yukl SA; Havlir DV; Greene WC; Wong JK
Nat Med; 2016 Jul; 22(7):807-11. PubMed ID: 27294875
[TBL] [Abstract][Full Text] [Related]
18. A stable latent reservoir for HIV-1 in resting CD4(+) T lymphocytes in infected children.
Persaud D; Pierson T; Ruff C; Finzi D; Chadwick KR; Margolick JB; Ruff A; Hutton N; Ray S; Siliciano RF
J Clin Invest; 2000 Apr; 105(7):995-1003. PubMed ID: 10749578
[TBL] [Abstract][Full Text] [Related]
19. HIV DNA subspecies persist in both activated and resting memory CD4+ T cells during antiretroviral therapy.
Murray JM; Zaunders JJ; McBride KL; Xu Y; Bailey M; Suzuki K; Cooper DA; Emery S; Kelleher AD; Koelsch KK;
J Virol; 2014 Mar; 88(6):3516-26. PubMed ID: 24403590
[TBL] [Abstract][Full Text] [Related]
20. Analysis of human immunodeficiency virus type 1 gene expression in latently infected resting CD4+ T lymphocytes in vivo.
Hermankova M; Siliciano JD; Zhou Y; Monie D; Chadwick K; Margolick JB; Quinn TC; Siliciano RF
J Virol; 2003 Jul; 77(13):7383-92. PubMed ID: 12805437
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
